Alzamend Neuro, Inc. (ALZN)
- Previous Close
0.6880 - Open
0.6857 - Bid --
- Ask --
- Day's Range
0.6850 - 0.7295 - 52 Week Range
0.6520 - 11.9100 - Volume
15,326 - Avg. Volume
56,875 - Market Cap (intraday)
4.94M - Beta (5Y Monthly) 0.02
- PE Ratio (TTM)
-- - EPS (TTM)
-1.8200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
21.00
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
www.alzamend.comRecent News: ALZN
Performance Overview: ALZN
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALZN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALZN
Valuation Measures
Market Cap
4.70M
Enterprise Value
4.42M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.36
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-166.84%
Return on Equity (ttm)
-1,196.26%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-12.4M
Diluted EPS (ttm)
-1.8200
Balance Sheet and Cash Flow
Total Cash (mrq)
282.87k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-4.58M